Side-by-side comparison of AI visibility scores, market position, and capabilities
Cleveland OH Midwest/Mountain West regional bank (NYSE: KEY) ~$7.8B FY2024 revenue; Scotiabank $2.8B equity investment 2024, KBCM middle market investment banking, competing with Huntington and Fifth Third.
KeyCorp is a Cleveland, Ohio-based regional bank holding company — publicly traded on the New York Stock Exchange (NYSE: KEY) as an S&P 500 Financials component — providing commercial and retail banking, investment banking, wealth management, and capital markets services through KeyBank National Association across a 15-state footprint primarily in the Midwest, Mountain West, Pacific Northwest, and Alaska through approximately 17,000 employees. In fiscal year 2024, KeyCorp reported net revenues of approximately $7.8 billion, with the company executing a significant strategic capital action: in August 2024, Bank of Nova Scotia (Scotiabank) agreed to invest $2.8 billion in KeyCorp through a 14.9% equity stake acquisition — providing KeyCorp with common equity Tier 1 capital to support balance sheet repositioning (selling low-yielding bond securities purchased in 2020-2021 at low rates, reinvesting at higher rates to improve net interest income trajectory) and to fund commercial banking growth. CEO Chris Gorman's strategy of repositioning KeyCorp from a diversified financial services company toward a "relationship bank" model emphasizes middle market commercial lending (companies with $25M-$2B in revenue), commercial mortgage banking, and KeyBanc Capital Markets investment banking as the differentiated businesses where KeyCorp generates above-average revenue per relationship compared to consumer banking. KeyCorp's investment banking arm (KeyBanc Capital Markets — KBCM) provides middle market companies with equity capital markets (ECM — IPOs, follow-on offerings, convertibles), debt capital markets (DCM — leveraged loans, high-yield bonds), and M&A advisory capabilities that regional bank-scaled investment banks rarely match.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.